CRISPR Researchers Engineer More Efficient Cas12a Variants for Genetic, Epigenetic, Base Editing

Feb 11, 2019

|

NEW YORK (GenomeWeb) – In a study published today in Nature Biotechnology, researchers in Keith Joung's lab at Massachusetts General Hospital described their efforts to engineer enhanced variants of the Cas12a nuclease that can target a wider range of protospacer adjacent motifs (PAM), have enhanced editing activity, and have reduced off-target effects.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Breaking News

The Scan

Bill to Ease Post-Conviction DNA Testing Access

The Oregon state Senate unanimously passed a bill that would make it easier for people convicted of crimes to initiate DNA testing of evidence, according to the Associated Press.

Ah, Feel Full Now

People reports that researchers have uncovered genetic variants that lead people to always feel full.

Life Insurers, Too, in Florida?

Florida state senators are to weigh a bill prohibiting life insurance companies from using genetic information in coverage decisions, according to Florida Politics.

This Week in Genome Research

In Genome Research this week: metagenomic sequencing assay that detects pathogens in cerebrospinal fluid, single-tube long fragment read approach, and more.

Featured White Papers

The WOLF 'Cuts' Time from CRISPR Workflows

Controlling Ribonuclease (RNase) with High Irradiance UV LED Light Engines

The Ultimate Guide to Mouse Clinical Trials

High Throughput RT-qPCR for Gene Expression Analysis

Apr

30

Featured Webinar

Novel Methods for Improving De Novo Transcriptome Annotation with Long-Read Transcript Sequencing

This webinar will discuss novel long-read transcript sequencing (LRTseq) methods for transcriptome annotation that could increase the efficiency and accuracy of future sequencing projects.

May

21

Featured Webinar

Implementation of qPCR Mutation Assays for Routine Use in a Hematology/Oncology Lab

This webinar will provide a first-hand look at how a hematology/oncology lab in the UK set up and validated three molecular assays for routine in-house use.

Menu